Module

State-of-the-Art First-line Treatment of MCL: Current and Novel Approaches

Source: Evolving Treatment Options and Future Directions in Mantle Cell Lymphoma

State-of-the-Art First-line Treatment of MCL: Current and Novel Approaches

Faculty:

Andrew D. Zelenetz, MD, PhD

CREDIT INFORMATION

Release Date: May 12, 2009

Expiration Date: May 11, 2010

Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Registered Nurses: 0.9 Nursing contact hours

Status: The activity is not currently available for credit.

Learning Objectives

Upon completion of this activity, participants should be able to:

Cite the latest data on prognostic indicators for survival among patients with mantle cell lymphoma
Review clinical trials data evaluating the role of rituximab in combination with standard or dose-intense chemotherapy regimens for the first-line treatment of mantle cell lymphoma
Discuss the safety and efficacy of adding radioimmunotherapy to chemotherapy regimens or in the setting of stem cell transplantation
Analyze results of recent clinical trials investigating the incorporation of newer agents into mantle cell lymphoma treatment

Topics covered include:

Introduction
Biologic Characteristics of MCL
MCL Staging and Diagnosis
Induction Therapy and the Role of Rituximab in the Treatment of MCL
Radioimmunotherapy for the Treatment of MCL
Bortezomib and Bendamustine for Newly Diagnosed MCL
Other Agents Under Investigation for Frontline MCL
Conclusion

Abstract

Click here to view abstract

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.